

# Alastair M Gray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7295359/publications.pdf>

Version: 2024-02-01

167  
papers

8,419  
citations

61857

43  
h-index

51492

86  
g-index

168  
all docs

168  
docs citations

168  
times ranked

11235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Utility of an Online Education Platform and Diabetes Personal Health Record: Analysis Over Ten Years. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 715-726.	1.3	6
2	Association between sternal wound complications and 10-year mortality following coronary artery bypass grafting. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 166, 532-539.e4.	0.4	6
3	Effect of total arterial grafting in the Arterial Revascularization Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 1002-1009.e6.	0.4	51
4	Cost-effectiveness of bilateral vs. single internal thoracic artery grafts at 10 years. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 324-332.	1.8	6
5	An Intuitive Risk Communication Tool to Enhance Patient-Provider Partnership in Diabetes Consultation. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 988-994.	1.3	1
6	Is comprehensive geriatric assessment hospital at home a cost-effective alternative to hospital admission for older people?. <i>Age and Ageing</i> , 2022, 51, .	0.7	30
7	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109152.	1.1	2
8	Hospital at Home admission avoidance with comprehensive geriatric assessment to maintain living at home for people aged 65 years and over: a RCT. , 2022, 10, 1-124.		6
9	Clinical Manifestation and Diagnostic Process of Celiac Disease in Poland-Comparison of Pediatric and Adult Patients in Retrospective Study. <i>Nutrients</i> , 2022, 14, 491.	1.7	14
10	Prognostic factors of 10-year mortality after coronary artery bypass graft surgery: a secondary analysis of the arterial revascularization trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	4
11	Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry. <i>Blood Advances</i> , 2022, 6, 909-919.	2.5	5
12	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. <i>Medical Decision Making</i> , 2022, 42, 599-611.	1.2	5
13	Single versus multiple arterial grafting in diabetic patients at 10 years: the Arterial Revascularization Trial. <i>European Heart Journal</i> , 2022, 43, 4644-4652.	1.0	19
14	Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1875.	3.8	49
15	Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study. <i>Health Technology Assessment</i> , 2022, 26, 1-156.	1.3	3
16	School-based screening for childhood anxiety problems and intervention delivery: a codesign approach. <i>BMJ Open</i> , 2022, 12, e058089.	0.8	3
17	Survival, Dependency, and Health-Related Quality of Life in Patients With Ruptured Intracranial Aneurysm: 10-Year Follow-up of the United Kingdom Cohort of the International Subarachnoid Aneurysm Trial. <i>Neurosurgery</i> , 2021, 88, 252-260.	0.6	18
18	Ten-year outcomes after off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 591-599.e8.	0.4	21

#	ARTICLE	IF	CITATIONS
19	Cost and quality-of-life impacts of community treatment orders (CTOs) for patients with psychosis: economic evaluation of the OCTET trial. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 85-95.	1.6	7
20	Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study. <i>Quality of Life Research</i> , 2021, 30, 867-879.	1.5	4
21	Association of Age With 10-Year Outcomes After Coronary Surgery in the Arterial Revascularization Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 18-26.	1.2	24
22	Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008983.	1.3	1
23	The impact of symptoms on quality of life before and after diagnosis of coeliac disease: the results from a Polish population survey and comparison with the results from the United Kingdom. <i>BMC Gastroenterology</i> , 2021, 21, 99.	0.8	15
24	Codesign and development of a primary school based pathway for child anxiety screening and intervention delivery: a protocol, mixed-methods feasibility study. <i>BMJ Open</i> , 2021, 11, e044852.	0.8	12
25	Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2-factorial, randomised controlled trial. <i>Lancet, The</i> , 2021, 398, 416-428.	6.3	53
26	Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus-Infected Adults in Vietnam. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab357.	0.4	0
27	Is Comprehensive Geriatric Assessment Admission Avoidance Hospital at Home an Alternative to Hospital Admission for Older Persons?. <i>Annals of Internal Medicine</i> , 2021, 174, 889-898.	2.0	69
28	Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). <i>Diabetic Medicine</i> , 2021, 38, e14656.	1.2	10
29	Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-158.	1.3	10
30	Comparison of Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting Techniques in the Arterial Revascularization Trial. <i>JAMA Cardiology</i> , 2021, 6, 1380.	3.0	31
31	A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality. <i>Clinical and Translational Radiation Oncology</i> , 2020, 20, 19-26.	0.9	13
32	Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1078-1085.	2.3	11
33	Preferences for interventions designed to increase cervical screening uptake in non-attending young women: How findings from a discrete choice experiment compare with observed behaviours in a trial. <i>Health Expectations</i> , 2020, 23, 202-211.	1.1	5
34	Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. <i>European Journal of Cancer</i> , 2020, 124, 178-185.	1.3	11
35	Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2020, 142, 1320-1329.	1.6	58
36	Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 154.	3.0	37

#	ARTICLE	IF	CITATIONS
37	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , 2020, 23, 1163-1170.	0.1	32
38	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020, 43, 2485-2492.	4.3	3
39	Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2ÅÅ– 2ÅÅ– 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning. <i>Value in Health</i> , 2020, 23, 1340-1348.	0.1	3
40	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	1.2	15
41	Which interactions matter in economic evaluations? A systematic review and simulation study. <i>BMC Medical Research Methodology</i> , 2020, 20, 109.	1.4	1
42	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	2.2	8
43	Who gets referred for knee or hip replacement? A theoretical model of the potential impact of evidence-based referral thresholds using data from a retrospective review of clinic records from an English musculoskeletal referral hub. <i>BMJ Open</i> , 2020, 10, e028915.	0.8	4
44	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312.	1.7	28
45	&lt;p&gt;Preferences for cervical cancer screening service attributes in rural China: a discrete choice experiment&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 881-889.	0.8	9
46	Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2405-2412.	2.2	10
47	A macroeconomic assessment of the impact of medical research expenditure: A case study of NIHR Biomedical Research Centres. <i>PLoS ONE</i> , 2019, 14, e0214361.	1.1	3
48	Family income and exposure to norovirus in childhood: Findings from the UK Millennium Cohort Study. <i>SSM - Population Health</i> , 2019, 8, 100445.	1.3	1
49	Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years. <i>New England Journal of Medicine</i> , 2019, 380, 437-446.	13.9	334
50	Surgical fixation with K-wires versus plaster casting in the treatment of dorsally displaced distal radius fractures: protocol for Distal Radius Acute Fracture Fixation Trial 2 (DRAFFT 2). <i>BMJ Open</i> , 2019, 9, e028474.	0.8	10
51	The impact of diagnosis on health-related quality of life in people with coeliac disease: a UK population-based longitudinal perspective. <i>BMC Gastroenterology</i> , 2019, 19, 68.	0.8	23
52	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	0.9	48
53	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179.	2.6	13
54	Five-year costs from a randomised comparison of bilateral and single internal thoracic artery grafts. <i>Heart</i> , 2019, 105, 1237-1243.	1.2	3

#	ARTICLE	IF	CITATIONS
55	&lt;p&gt;The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice&lt;/p&gt;. Patient Related Outcome Measures, 2019, Volume 10, 9-24.	0.7	86
56	Impact of Vision Loss on Health-Related Quality of Life in Trinidad and Tobago. Ophthalmology, 2019, 126, 1055-1058.	2.5	4
57	Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis. BMJ Open, 2019, 9, e031356.	0.8	7
58	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology, 2019, 106, 108-120.	2.4	49
59	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	6.3	697
60	Body mass index and use and costs of primary care services among women aged 55â€“79 years in England: a cohort and linked data study. International Journal of Obesity, 2019, 43, 1839-1848.	1.6	11
61	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. Journal of Diabetes and Its Complications, 2019, 33, 69-74.	1.2	3
62	Healthâ€related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 525-532.	2.2	21
63	The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling. Health Technology Assessment, 2019, 23, 1-216.	1.3	28
64	Analysis of hydration and antiemetics policies in preventing cisplatin-related gastrointestinal and renal toxicities in low-risk human papillomavirus positive-oropharyngeal cancer (HPV+OPC) patients undergoing chemoradiation in De-ESCALaTE trial.. Journal of Clinical Oncology, 2019, 37, 6076-6076.	0.8	0
65	Incidence and clinical implications of intraoperative bilateral internal thoracic artery graft conversion: Insights from the Arterial Revascularization Trial. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2346-2355.e6.	0.4	28
66	Safety of Perioperative Aprotinin Administration During Isolated Coronary Artery Bypass Graft Surgery: Insights From the ART (ArterialâRevascularization Trial). Journal of the American Heart Association, 2018, 7, .	1.6	10
67	Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions. Medical Decision Making, 2018, 38, 476-486.	1.2	13
68	Resource utilisation and costs in predementia and dementia: a systematic review protocol. BMJ Open, 2018, 8, e019060.	0.8	11
69	Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?. Pharmacoeconomics, 2018, 36, 253-257.	1.7	11
70	Health system dynamics analysis of eyecare services in Trinidad and Tobago and progress towards Vision 2020 Goals. Health Policy and Planning, 2018, 33, 70-84.	1.0	10
71	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.4	25
72	Off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1545-1553.e7.	0.4	22

#	ARTICLE	IF	CITATIONS
73	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.1	63
74	Associations between preoperative Oxford hip and knee scores and costs and quality of life of patients undergoing primary total joint replacement in the NHS England: an observational study. <i>BMJ Open</i> , 2018, 8, e019477.	0.8	26
75	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1732-1739.	2.2	5
76	Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e019082.	0.8	17
77	Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC). <i>Journal of Medical Screening</i> , 2018, 25, 99-109.	1.1	12
78	Arthroscopic subacromial decompression for subacromial shoulder pain (CSAW): a multicentre, pragmatic, parallel group, placebo-controlled, three-group, randomised surgical trial. <i>Lancet</i> , The, 2018, 391, 329-338.	6.3	343
79	Knee replacement. <i>Lancet</i> , The, 2018, 392, 1672-1682.	6.3	449
80	Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level. <i>BMC Medical Research Methodology</i> , 2018, 18, 87.	1.4	42
81	Comparison of statistical approaches for analyzing incomplete longitudinal patient-reported outcome data in randomized controlled trials. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 197-209.	0.7	10
82	Nudging people with Type 2 diabetes towards better self-management through personalized risk communication: A pilot randomized controlled trial in primary care. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00022.	1.0	12
83	Partial factorial trials: comparing methods for statistical analysis and economic evaluation. <i>Trials</i> , 2018, 19, 442.	0.7	7
84	What do we know about managing Dupuytren's disease cost-effectively?. <i>BMC Musculoskeletal Disorders</i> , 2018, 19, 34.	0.8	11
85	Risk attitudes of people with "manageable" chronic disease: An analysis under prospect theory. <i>Social Science and Medicine</i> , 2018, 214, 144-153.	1.8	24
86	Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer's disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.. <i>BMJ Open</i> , 2018, 8, e020638.	0.8	8
87	Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD). <i>Wellcome Open Research</i> , 2018, 3, 156.	0.9	3
88	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-64.	1.3	28
89	Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren's disease: Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD). <i>Wellcome Open Research</i> , 2018, 3, 156.	0.9	1
90	Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e013592.	0.8	22

#	ARTICLE	IF	CITATIONS
91	Impact of dual antiplatelet therapy after coronary artery bypass surgery on 1-year outcomes in the Arterial Revascularization Trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 456-461.	0.6	7
92	Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations. <i>Statistics in Medicine</i> , 2017, 36, 2814-2830.	0.8	23
93	Hospital costs in relation to body-mass index in 1.1 million women in England: a prospective cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e214-e222.	4.7	30
94	One-year costs of bilateral or single internal mammary grafts in the Arterial Revascularisation Trial. <i>Heart</i> , 2017, 103, 1719-1726.	1.2	14
95	Body mass index and healthcare costs: a systematic literature review of individual participant data studies. <i>Obesity Reviews</i> , 2017, 18, 869-879.	3.1	91
96	Associations Between Adding a Radial Artery Graft to Single and Bilateral Internal Thoracic Artery Grafts and Outcomes. <i>Circulation</i> , 2017, 136, 454-463.	1.6	61
97	Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study. <i>Diabetes Therapy</i> , 2017, 8, 1031-1045.	1.2	9
98	Reducing social isolation and loneliness in older people: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e013778.	0.8	130
99	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
100	Changing experience of adverse medical events in the National Health Service: Comparison of two population surveys in 2001 and 2013. <i>Social Science and Medicine</i> , 2017, 195, 83-89.	1.8	2
101	Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 426-436.	0.8	10
102	Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 203-211.	3.1	62
103	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890.	1.2	21
104	Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England. <i>BMJ Open</i> , 2017, 7, e017186.	0.8	31
105	Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH). <i>Health and Quality of Life Outcomes</i> , 2017, 15, 250.	1.0	26
106	A multi-centre randomised trial to compare the effectiveness of geriatrician-led admission avoidance hospital at home versus inpatient admission. <i>Trials</i> , 2017, 18, 491.	0.7	21
107	Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3507-3507.	0.8	17
108	Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. <i>Wellcome Open Research</i> , 2017, 2, 37.	0.9	13



#	ARTICLE	IF	CITATIONS
109	Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.. Wellcome Open Research, 2017, 2, 37.	0.9	15
110	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. Programme Grants for Applied Research, 2017, 5, 1-290.	0.4	12
111	Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial. Movement Disorders, 2016, 31, 1173-1182.	2.2	27
112	Pedicle and skeletonized single and bilateral internal thoracic artery grafts and the incidence of sternal wound complications: Insights from the Arterial Revascularization Trial. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 270-276.	0.4	149
113	Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts. New England Journal of Medicine, 2016, 375, 2540-2549.	13.9	337
114	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 348-354.	0.9	8
115	A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine, 2016, 84, 48-56.	1.6	83
116	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	2.1	42
117	Economic evaluation of healthcare interventions: old and new directions: Table 1:. Oxford Review of Economic Policy, 2016, 32, 102-121.	1.0	17
118	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	2.1	19
119	The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literature. Quality of Life Research, 2016, 25, 1613-1623.	1.5	53
120	Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Quality of Life Research, 2016, 25, 275-281.	1.5	14
121	The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review*. Nephrology Dialysis Transplantation, 2016, 31, 46-56.	0.4	76
122	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC). Health Technology Assessment, 2016, 20, 1-138.	1.3	36
123	PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. International Journal of Technology Assessment in Health Care, 2015, 31, 230-235.	0.2	7
124	Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England. Critical Care, 2015, 19, 276.	2.5	30
125	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. Medical Decision Making, 2015, 35, NP1-NP8.	1.2	1
126	The CSAW Study (Can Shoulder Arthroscopy Work?) – a placebo-controlled surgical intervention trial assessing the clinical and cost effectiveness of arthroscopic subacromial decompression for shoulder pain: study protocol for a randomised controlled trial. Trials, 2015, 16, 210.	0.7	39



#	ARTICLE	IF	CITATIONS
127	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. <i>BMC Nephrology</i> , 2015, 16, 65.	0.8	82
128	UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia. <i>BMJ Open</i> , 2015, 5, e006648-e006648.	0.8	56
129	The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration. <i>Pharmacoeconomics</i> , 2015, 33, 993-1011.	1.7	70
130	Mapping from the Parkinson's Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L. <i>Medical Decision Making</i> , 2015, 35, 902-911.	1.2	26
131	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 437-443.	1.0	1
132	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 106.	1.0	13
133	Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement. <i>Pharmacoeconomics</i> , 2015, 33, 985-991.	1.7	21
134	Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement. <i>Journal of Medical Economics</i> , 2015, 18, 851-857.	1.0	4
135	Effects of on-pump and off-pump surgery in the Arterial Revascularization Trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 1059-1065.	0.6	35
136	CryptoDex: A randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial. <i>Trials</i> , 2014, 15, 441.	0.7	19
137	Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: Does the ADDITION Validation Add Up?. <i>Value in Health</i> , 2014, 17, 895-896.	0.1	1
138	THE EFFECT OF DIABETES COMPLICATIONS ON HEALTH-RELATED QUALITY OF LIFE: THE IMPORTANCE OF LONGITUDINAL DATA TO ADDRESS PATIENT HETEROGENEITY. <i>Health Economics (United Kingdom)</i> , 2014, 23, 487-500.	0.8	84
139	A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT). <i>Health Technology Assessment</i> , 2014, 18, 1-235, vii-viii.	1.3	98
140	Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. <i>Quality of Life Research</i> , 2013, 22, 683-694.	1.5	51
141	Antibiotic management and early discharge from hospital: an economic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2297-2302.	1.3	46
142	Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. <i>BMJ Open</i> , 2012, 2, e000332.	0.8	144
143	Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. <i>Cardiovascular Diabetology</i> , 2012, 11, 56.	2.7	33
144	Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. <i>BMJ: British Medical Journal</i> , 2011, 342, d1548-d1548.	2.4	232

#	ARTICLE	IF	CITATIONS
145	Impact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population survey. BMC Health Services Research, 2010, 10, 105.	0.9	93
146	Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). European Heart Journal, 2010, 31, 2470-2481.	1.0	344
147	Obesity as Market Failure: Could a "Deliberative Economy"™ Overcome the Problems of Paternalism?. Kyklos, 2009, 62, 182-190.	0.7	35
148	Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. BMJ: British Medical Journal, 2009, 338, a3110-a3110.	2.4	123
149	Cost-effectiveness analyses alongside randomised clinical trials. Clinical Trials, 2006, 3, 538-542.	0.7	17
150	Cost-Utility Analysis of Physiotherapy Treatment Compared With Physiotherapy Advice in Low Back Pain. Spine, 2006, 31, 1381-1387.	1.0	59
151	Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265]. Trials, 2006, 7, 7.	0.7	97
152	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20%536 people. BMJ: British Medical Journal, 2006, 333, 1145.	2.4	80
153	Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping. Medical Decision Making, 2006, 26, 18-29.	1.2	188
154	Economic Evaluation of Ultrasonography in the Diagnosis and Management of Developmental Hip Dysplasia in the United Kingdom and Ireland. Journal of Bone and Joint Surgery - Series A, 2005, 87, 2472.	1.4	37
155	The Economics of Clinical Negligence Reform in England. Economic Journal, 2004, 114, F272-F292.	1.9	17
156	Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ: British Medical Journal, 2002, 325, 860-860.	2.4	72
157	Estimating the relationship between disease progression and cost of care in dementia. British Journal of Psychiatry, 2002, 181, 36-42.	1.7	84
158	Quality of life outcomes following surgical treatment of Parkinson's disease. Movement Disorders, 2002, 17, 68-75.	2.2	32
159	Randomised controlled trial of an interactive multimedia decision aid on benign prostatic hypertrophy in primary. BMJ: British Medical Journal, 2001, 323, 493-493.	2.4	160
160	Randomised controlled trial of an interactive multimedia decision aid on hormone replacement therapy in primary. BMJ: British Medical Journal, 2001, 323, 490-490.	2.4	131
161	Current cost of medical negligence in NHS hospitals: analysis of claims database. BMJ: British Medical Journal, 2000, 320, 1567-1571.	2.4	65
162	Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ: British Medical Journal, 2000, 320, 1373-1378.	2.4	269

#	ARTICLE	IF	CITATIONS
163	The reform of legal aid in England and Wales. <i>Fiscal Studies</i> , 1999, 20, 261-286.	0.8	12
164	Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes. <i>BMJ: British Medical Journal</i> , 1998, 316, 1786-1791.	2.4	181
165	The use of out of hours health services: a cross sectional survey. <i>BMJ: British Medical Journal</i> , 1998, 316, 524-527.	2.4	53
166	Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis. <i>BMJ: British Medical Journal</i> , 1998, 316, 1791-1796.	2.4	138
167	Economic Evaluation for Decision-making. , 0, , 59-75.		0